明年还要花300亿!百济神州“豪赌”突进

健识局
03 Mar

超越 恒瑞医药 登顶A股药企市值榜首后, 百济神州 又发布了2024年财报。2月27日晚间,百济神州在美股、港股发布2024年业绩财报,同时公布A股业绩快报。根据财报显示:百济神州全年总营收达272.14亿元,同比增长55%。其中泽布替尼、替雷利珠单抗的销售收入分别是188.59亿元、44.67亿元,是推动营收增长的主要动力。营收快速增长,使百济神州的经营亏损显著收窄。2025年,百济神州归属于...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10